An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02997176 |
|
Recruitment Status :
Completed
First Posted : December 19, 2016
Results First Posted : February 25, 2021
Last Update Posted : February 25, 2021
|
Sponsor:
Pfizer
Collaborator:
Medivation, Inc.
Information provided by (Responsible Party):
Pfizer
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a trial to investigate the pharmacokinetics (PK) and the safety of talazoparib in patients with advanced solid tumors and impaired hepatic function.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Advanced Solid Tumors | Drug: Talazoparib | Phase 1 |
At the end of the study, patients with no clinically significant toxicities, no contraindications to continue treatment with talazoparib, and no disease progression (underlying cancer progression) may be eligible to continue talazoparib treatment in a separate open-label extension study. The decision to allow the patient to continue dosing with talazoparib in an open-label extension (OLE) study will be based on potential overall benefit-risk and patient meeting eligibility criteria for OLE.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 38 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A PHASE I OPEN-LABEL PHARMACOKINETICS AND SAFETY STUDY OF TALAZOPARIB (MDV3800) IN PATIENTS WITH ADVANCED SOLID TUMORS AND NORMAL OR VARYING DEGREES OF HEPATIC IMPAIRMENT |
| Actual Study Start Date : | September 30, 2016 |
| Actual Primary Completion Date : | February 12, 2020 |
| Actual Study Completion Date : | February 12, 2020 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Talazoparib
| Arm | Intervention/treatment |
|---|---|
| Experimental: Group A (control, normal hepatic function) |
Drug: Talazoparib
Daily oral doses of talazoparib 0.5 mg
Other Names:
|
| Experimental: Group B (mild hepatic dysfunction) |
Drug: Talazoparib
Daily oral doses of talazoparib 0.5 mg
Other Names:
|
| Experimental: Group C (moderate hepatic dysfunction) |
Drug: Talazoparib
Daily oral doses of talazoparib 0.5 mg
Other Names:
|
| Experimental: Group D (severe hepatic dysfunction) |
Drug: Talazoparib
Daily oral doses of talazoparib 0.5 mg
Other Names:
|
Primary Outcome Measures :
- Area Under the Free Plasma Concentration Time Curve From Zero to 24 Hours (AUC0-24) of Talazoparib on Day 22 [ Time Frame: Pre-dose (24 hours +/- 60 minutes from the previous dose on Day 21 but within 60 minutes prior to next dose), 0.5, 1, 2, 4, 6, anytime from 8 to 12 and 24 hours post-dose on Day 22 ]AUC0-24 of talazoparib was defined as the area under the free plasma concentration time curve from time 0 to 24 hours post-dose.
- Maximum Observed Plasma Concentration (Cmax) of Talazoparib on Day 22 [ Time Frame: Pre-dose (24 hours +/- 60 minutes from the previous dose on Day 21 but within 60 minutes prior to next dose), 0.5, 1, 2, 4, 6, anytime from 8 to 12 and 24 hours post-dose on Day 22 ]Cmax was defined as the maximum observed plasma concentration of talazoparib.
- Unbound Area Under the Free Plasma Concentration Time Curve From Zero to 24 Hours (AUC0-24u) of Talazoparib on Day 22 [ Time Frame: Pre-dose (24 hours +/- 60 minutes from the previous dose on Day 21 but within 60 minutes prior to next dose), 0.5, 1, 2, 4, 6, anytime from 8 to 12 and 24 hours post-dose on Day 22 ]AUC0-24u for unbound talazoparib was defined as the area under the free plasma concentration time curve from time 0 to 24 hours post-dose. AUC0-24u = fu*AUC0-24. fu= Fraction of Unbound (fu) Plasma.
- Unbound Maximum Observed Plasma Concentration (Cmaxu) of Talazoparib on Day 22 [ Time Frame: Pre-dose (24 hours +/- 60 minutes from the previous dose on Day 21 but within 60 minutes prior to next dose), 0.5, 1, 2, 4, 6, anytime from 8 to 12 and 24 hours post-dose on Day 22 ]Cmaxu was defined as the maximum observed plasma concentration for unbound talazoparib. Cmaxu = fu*Cmax.
Secondary Outcome Measures :
- Area Under the Free Plasma Concentration Time Curve From Zero to 24 Hours (AUC0-24) of Talazoparib on Day 1 [ Time Frame: Pre-dose (within 60 minutes prior to dose), 0.5, 1, 2, 4, 6, anytime between 8 to 12 and 24 hours post-dose on Day 1 ]AUC0-24 of talazoparib was defined as the area under the free plasma concentration time curve from time 0 to 24 hours post-dose.
- Maximum Observed Plasma Concentration (Cmax) of Talazoparib on Day 1 [ Time Frame: Pre-dose (within 60 minutes prior to dose), 0.5, 1, 2, 4, 6, anytime between 8 to 12 and 24 hours post-dose on Day 1 ]Cmax was defined as the maximum observed plasma concentration of talazoparib.
- Time to Reach Maximum Observed Plasma Concentration (Tmax) of Talazoparib on Day 1 [ Time Frame: Pre-dose (within 60 minutes prior to dose), 0.5, 1, 2, 4, 6, anytime between 8 to 12 and 24 hours post-dose on Day 1 ]Tmax was defined as the time to reach maximum observed plasma concentration of talazoparib.
- Fraction of Unbound (fu) Plasma Talazoparib on Day 1 [ Time Frame: Pre-dose (within 60 minutes prior to dose), 0.5, 1, 2, 4, 6, anytime between 8 to 12 and 24 hours post-dose on Day 1 ]Fraction of unbound drug (fu) was defined as the ratio of unbound drug concentration to the total drug concentration and reported as percentage (%).
- Unbound Area Under the Free Plasma Concentration Time Curve From Zero to 24 Hours (AUC0-24u) of Talazoparib on Day 1 [ Time Frame: Pre-dose (within 60 minutes prior to dose), 0.5, 1, 2, 4, 6, anytime between 8 to 12 and 24 hours post-dose on Day 1 ]AUC0-24u for unbound talazoparib was defined as the area under the free plasma concentration time curve from time 0 to 24 hours post-dose. AUC0-24u = fu*AUC0-24.
- Unbound Maximum Observed Plasma Concentration (Cmaxu) of Talazoparib on Day 1 [ Time Frame: Pre-dose (within 60 minutes prior to dose), 0.5, 1, 2, 4, 6, anytime between 8 to 12 and 24 hours post-dose on Day 1 ]Cmaxu was defined as the maximum observed plasma concentration for unbound talazoparib. Cmaxu = fu*Cmax
- Plasma Trough Concentration (Ctrough) of Talazoparib on Day 8, 15 and 22 [ Time Frame: Pre-dose on Day 8, 15 and 22 ]Ctrough was defined as plasma trough (pre-dose) concentration of talazoparib. Acceptance criteria for Ctrough on Day 15 and Day 22: received 10 consecutive days of dosing immediately before PK sampling day; Sample drawn within 24 +/-2 hours of the previous dose, and not more than +10 minute after the drug administration on the PK collection day. Ctrough on Day 8: received 7 consecutive days of dosing immediately before PK sampling day; sample drawn within 24 +/- 2 hours of the previous dose, and not more than +10 minute after the drug administration on the PK collection day.
- Time to Reach Maximum Observed Plasma Concentration (Tmax) of Talazoparib on Day 22 [ Time Frame: Pre-dose (24 hours +/- 60 minutes from the previous dose on Day 21 but within 60 minutes prior to next dose), 0.5, 1, 2, 4, 6, anytime from 8 to 12 and 24 hours post-dose on Day 22 ]Tmax was defined as the time to reach maximum observed plasma concentration of talazoparib.
- Fraction of Unbound (fu) Plasma Talazoparib on Day 22 [ Time Frame: Pre-dose (24 hours +/- 60 minutes from the previous dose on Day 21 but within 60 minutes prior to next dose), 0.5, 1, 2, 4, 6, anytime from 8 to 12 and 24 hours post-dose on Day 22 ]Fraction of unbound drug (fu) was defined as the ratio of unbound drug concentration to the total drug concentration and reported as percentage (%).
- Accumulation Ratio (Rac) of Plasma Talazoparib [ Time Frame: Pre-dose (within 60 minutes prior to dose) on Day 1, pre-dose(24 hours +/- 60 minutes from the previous dose on Day 21 but within 60 minutes prior to next dose) on Day 22 and 0.5, 1, 2, 4, 6, anytime between 8 to 12 and 24 hours post-dose on Days 1 and 22 ]Accumulation ratio for AUC0-24 was calculated as area under the curve from time zero to 24 hours on Day 22 divided by area under the curve from time zero to 24 hours on Day 1.
- Apparent Clearance (CL/F) of Plasma Talazoparib on Day 22 [ Time Frame: Pre-dose (24 hours +/- 60 minutes from the previous dose on Day 21 but within 60 minutes prior to next dose), 0.5, 1, 2, 4, 6, anytime from 8 to 12 and 24 hours post-dose on Day 22 ]Talazoparib clearance is a measure of the rate at which talazoparib is metabolized or eliminated by normal biological processes.
- Unbound Apparent Clearance (CLu/F) of PlasmaTalazoparib on Day 22 [ Time Frame: Pre-dose (24 hours +/- 60 minutes from the previous dose on Day 21 but within 60 minutes prior to next dose), 0.5, 1, 2, 4, 6, anytime from 8 to 12 and 24 hours post-dose on Day 22 ]Clearance of unbound talazoparib is a measure of the rate at which unbound talazoparib is metabolized or eliminated by normal biological processes.
- Amount of Talazoparib Excreted Unchanged in Urine From Time Zero to 24 Hours (Ae 0-24) on Day 1 [ Time Frame: A single void at pre-dose, post-dose at any time between 0 to 12 and any time between 12 to 24 hours on Day 1 ]Ae 0-24 is the amount of talazoparib excreted unchanged in urine from time 0 to 24 hours post dose.
- Percentage of Talazoparib Excreted in Urine From Time Zero to 24 Hours (Ae 0-24%) on Day 1 [ Time Frame: A single void at pre-dose, post-dose at any time between 0 to 12 and any time between 12 to 24 hours on Day 1 ]Ae0-24% was defined as the amount of talazoparib excreted in urine from time 0 to 24 hours expressed as percentage of administered dose.
- Amount of Talazoparib Excreted Unchanged in Urine From Time Zero to 24 Hours (Ae 0-24) on Day 22 [ Time Frame: Urine voided post-dose at any time between 0 to 12 and any time between 12 to 24 hours on Day 22 ]Ae 0-24 is the amount of talazoparib excreted unchanged in urine from time 0 to 24 hours post dose.
- Percentage of Talazoparib Excreted in Urine From Time 0 to 24 Hours (Ae 0-24%) on Day 22 [ Time Frame: Urine voided post-dose at any time between 0 to 12 and any time between 12 to 24 hours (hrs) on Day 22 ]Ae 0-24% was defined as the amount of talazoparib excreted in urine from time 0 to 24 hours expressed as percentage of administered dose.
- Renal Clearance (CLr) of Talazoparib on Day 22 [ Time Frame: Ae: Post-dose at any time between 0 to 12, 12 to 24 hrs on Day 22; AUC0-24: Pre-dose (24 hrs +/- 60 minutes from previous dose on Day 21 but within 60 minutes prior to next dose), 0.5, 1, 2, 4, 6, any time between 8 to12, 24 hrs post-dose on Day 22 ]Renal clearance was calculated as cumulative amount of drug excreted in urine during the 24 hours dosing interval (Ae) divided by area under the plasma concentration time-curve from time zero to 24 hours post dose (AUC0-24).
- Number of Participants With Clinically Significant Laboratory Abnormalities [ Time Frame: Baseline up to 30 days after last dose of study drug (up to 52 days) ]Clinically significant laboratory abnormalities included aspartate transaminase (AST) or alanine aminotransferase (ALT) >=3 times ULN (>5 *ULN if baseline ALT/AST is >3 *ULN) and total bilirubin (TBL) >2 times ULN or INR >1.5, AST or ALT >=3 times ULN with signs and symptoms consistent with hepatitis and/or eosinophilia (>=500 eosinophils/microliter).
- Change From Baseline in Vital Sign -Blood Pressure at Day 2, 8, 15, 22 and End of Study [ Time Frame: Baseline, Day 2, 8, 15, 22 and End of Study (Day 52) ]Systolic blood pressure and diastolic blood pressure were evaluated for examination of vital signs.
- Change From Baseline in Vital Sign- Heart Rate at Day 2, 8, 15, 22 and End of Study [ Time Frame: Baseline, Day 2, 8, 15, 22 and End of Study (Day 52) ]Heart rate was measured in beats per minute.
- Change From Baseline in Vital Sign- Respiratory Rate at Day 8, 15, 22 and End of Study [ Time Frame: Baseline, Day 8, 15, 22 and End of Study (Day 52) ]Respiratory rate was measured in terms of breaths per minute.
- Change From Baseline in Vital Sign- Weight at Day 8, 15, 22 and End of Study [ Time Frame: Baseline, Day 8, 15, 22 and End of Study (Day 52) ]
- Number of Participants Who Met the Pre-specified 12-Lead Electrocardiogram (ECG) Criteria [ Time Frame: Baseline up to 30 days after last dose of study drug (up to 52 days) ]Pre-specified 12-Lead electrocardiogram (ECG) Criteria: QTCF (Fridericia's correction formula) : >=450 to <480 milliseconds, >=480 to <500 milliseconds, >=500 milliseconds, increase from baseline >=30 - <60, increase from baseline >=60, PR interval: >=300 milliseconds, increase from baseline >=25%; QRS duration: >=140 milliseconds, increase from baseline >=50%; QT interval: >=500 milliseconds; QT Interval: >= 500 milliseconds.
- Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status [ Time Frame: Screening (2 to 28 days prior to Day 1), Day -1 (1 day prior to Day 1), safety follow up (Visit up to Day 52) ]As per ECOG, participant's performance status was measured as: 0=fully active/able to carry on all pre-disease activities without restriction; 1= restricted in physically strenuous activity but ambulatory and able to carry out work of a light and sedentary nature, e.g., light housework, office work; 2= ambulatory and capable of all self-care, but unable to carry out any work activities, up and about more than 50% of waking hours; 3=capable of only limited self-care, confined to bed/chair >50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed/chair.
Other Outcome Measures:
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [ Time Frame: Baseline up to 30 days after last dose of study drug (up to 52 days) ]An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. TEAEs were events between first dose of Talazoparib and up to 30 days after the last dose of Talazoparib (up to 52 days) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and all non-SAEs.
- Number of Participants With TEAEs Leading to Study Drug Discontinuation [ Time Frame: Baseline up to 30 days after last dose of study drug (up to 52 days) ]An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent were events between first dose of Talazoparib and up to 30 days after the last dose of Talazoparib (up to 52 days) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs. Number of participants with TEAEs leading to study drug discontinuation are reported.
- Number of Participants With TEAEs Resulting in Death [ Time Frame: Baseline up to 30 days after last dose of study drug (up to 52 days) ]An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent were events between first dose of Talazoparib and up to 30 days after the last dose of Talazoparib (up to 52 days) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs. Number of participants with TEAEs resulting in death are reported.
- Number of Participants With Treatment Emergent Treatment Related Adverse Events and SAEs [ Time Frame: Baseline up to 30 days after last dose of study drug (up to 52 days) ]A treatment-related adverse event was any untoward medical occurrence attributed to talazoparib in a participant who received talazoparib. A treatment-related serious adverse event was a treatment-related adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of dying); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; Congenital anomaly. Relatedness to talazoparib was assessed by the investigator.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Signed and dated Informed Consent Form (by the patient or a legally acceptable representative as per the local regulations).
- Female or male at least 18 years of age.
- Histologically or cytologically confirmed advanced solid tumor with no available standard treatment options in the opinion of the Investigator
- Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2.
- Expected life expectancy of ≥ 3 months.
- Able to swallow the study drug (no contraindication to oral agents).
- Hepatic function at screening and enrollment as defined by the NCI organ dysfunction working group (NCI-ODWG) criteria.
- Adequate other organ function at screening and enrollment.
- Female patients of childbearing potential must have a negative serum pregnancy test at screening and must agree to use a highly effective form of contraception from the time of the first dose of study drug through 7 months after the last dose of study drug.
- Male patients must agree to use a condom when having sex with a pregnant woman or with a non-pregnant female partner of childbearing potential, from 21 days before the first dose of study drug through 4 months after last dose of study drug.
- Female patients must not be breastfeeding at screening nor during the study participation until 7 months after the last dose of the study drug.
- Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.
Exclusion Criteria:
- Treatment within 14 days or five half lives prior to enrollment whichever is longer with any type of systemic anticancer-therapy or any investigational drug
- Have not recovered (recovery is defined as CTCAE grade ≤ 1) from the acute toxicities of previous anticancer standard or investigational therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements.
- Major surgery within 28 days prior to enrollment.
- Serious accompanying cardiac disorder
- Active known or suspected brain metastasis or active leptomeningeal disease needing treatment
- Symptomatic or impending spinal cord compression or cauda equine syndrome
- Has undergone a liver transplant, kidney transplant or nephrectomy.
- Prior allergic reaction or severe intolerance (meeting the criteria for a serious adverse event, a grade 3 or 4 AE, or permanent treatment discontinuation) to a poly ADP ribose polymerase (PARP) inhibitor.
- Known myelodysplastic syndrome
- Seropositive for human immunodeficiency virus (HIV).
- Any serious or unstable medical condition that interferes with ability to tolerate treatment or assessments associated with the protocol.
- Gastrointestinal disorder affecting absorption.
- Known or suspected hypersensitivity to any of the talazoparib capsule components.
- Any condition or reason that interferes with ability to participate in the study, tolerate treatment or assessments associated with the protocol, causes undue risk, or complicates the interpretation of safety data, in the opinion of the Investigator or Medical Monitor
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02997176
Locations
| United States, California | |
| UCLA Hematology/Oncology - Alhambra | |
| Alhambra, California, United States, 91801 | |
| CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center | |
| Bakersfield, California, United States, 93309 | |
| St. Joseph Heritage Healthcare | |
| Fullerton, California, United States, 92835 | |
| St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare | |
| Fullerton, California, United States, 92835 | |
| UCLA Hematology/Oncology | |
| Los Angeles, California, United States, 90095 | |
| UCLA Hematology/Oncology - Porter Ranch | |
| Porter Ranch, California, United States, 91326 | |
| UCLA Hematology/Oncology - Santa Monica | |
| Santa Monica, California, United States, 90404 | |
| UCLA Torrance Oncology | |
| Torrance, California, United States, 90505 | |
| UCLA Hematology/Oncology - Santa Clarita | |
| Valencia, California, United States, 91355 | |
| United States, Florida | |
| Orlando Health, Inc. | |
| Orlando, Florida, United States, 32806 | |
| United States, Texas | |
| The University of Texas MD Anderson Cancer Center | |
| Houston, Texas, United States, 77030 | |
Sponsors and Collaborators
Pfizer
Medivation, Inc.
Investigators
| Study Director: | Pfizer Pfizer CT.gov Call Center | Pfizer |
Study Documents (Full-Text)
Documents provided by Pfizer:
Documents provided by Pfizer:
Study Protocol [PDF] September 14, 2018
Statistical Analysis Plan [PDF] December 9, 2019
Additional Information:
| Responsible Party: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT02997176 |
| Other Study ID Numbers: |
MDV3800-02 C3441002 ( Other Identifier: Alias Study Number ) |
| First Posted: | December 19, 2016 Key Record Dates |
| Results First Posted: | February 25, 2021 |
| Last Update Posted: | February 25, 2021 |
| Last Verified: | February 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Plan Description: | Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests. |
Additional relevant MeSH terms:
|
Talazoparib Poly(ADP-ribose) Polymerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |